POCI
Price
$5.00Alerts
Change
-$0.05 (-0.99%)
Updated
Nov 12 closing price
Capitalization
53.19M
3 days until earnings call
Intraday BUY SELL Signals
STXS
Price
$0.85Alerts
Change
-$0.05 (-5.56%)
Updated
Nov 12 closing price
Capitalization
109.22M
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

POCI vs STXS

POCI vs STXS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
POCI vs. STXS commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is POCI is a Hold and STXS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for POCI with price predictions
Nov 12, 2026

POCI in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026

The 10-day moving average for POCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 22 of 27 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on POCI as a result. In 91 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for POCI just turned positive on October 29, 2026. Looking at past instances where POCI's MACD turned positive, the stock continued to rise in 38 of 55 cases over the following month. The odds of a continued upward trend are 69%.

POCI moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where POCI advanced for three days, in 113 of 165 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 107 of 152 cases where POCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for POCI moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 18 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 60 cases where POCI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where POCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

POCI broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.614) is normal, around the industry mean (4.964). P/E Ratio (-11.302) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.113) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. POCI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for STXS with price predictions
Nov 12, 2026

STXS's Stochastic Oscillator descending into oversold zone

The Stochastic Oscillator for STXS moved into oversold territory on November 12, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for STXS just turned positive on November 05, 2026. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.

Following a +8.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 152 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STXS as a result. In 78 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for STXS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.921) is normal, around the industry mean (4.964). P/E Ratio (-4.542) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
POCI vs STXS: Fundamental Ratings
POCI
STXS
OUTLOOK RATING
1..100
1510
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4385
P/E GROWTH RATING
1..100
6215
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

POCI's Valuation (20) in the null industry is significantly better than the same rating for STXS (94) in the Medical Specialties industry. This means that POCI’s stock grew significantly faster than STXS’s over the last 12 months.

POCI's Profit vs Risk Rating (100) in the null industry is in the same range as STXS (100) in the Medical Specialties industry. This means that POCI’s stock grew similarly to STXS’s over the last 12 months.

POCI's SMR Rating (96) in the null industry is in the same range as STXS (100) in the Medical Specialties industry. This means that POCI’s stock grew similarly to STXS’s over the last 12 months.

POCI's Price Growth Rating (43) in the null industry is somewhat better than the same rating for STXS (85) in the Medical Specialties industry. This means that POCI’s stock grew somewhat faster than STXS’s over the last 12 months.

STXS's P/E Growth Rating (15) in the Medical Specialties industry is somewhat better than the same rating for POCI (62) in the null industry. This means that STXS’s stock grew somewhat faster than POCI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
POCISTXS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
66%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 13, 2026
Stock price -- (POCI: $5.00 vs. STXS: $0.85)
Brand notoriety: POCI and STXS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: POCI: 110% vs. STXS: 211%
Market capitalization -- POCI: $53.19M vs. STXS: $109.22M
POCI [@Pharmaceuticals: Other] is valued at $53.19M. STXS’s [@Pharmaceuticals: Other] market capitalization is $109.22M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

POCI’s FA Score shows that 1 FA rating(s) are green while STXS’s FA Score has 1 green FA rating(s).

  • POCI’s FA Score: 1 green, 4 red.
  • STXS’s FA Score: 1 green, 4 red.
According to our system of comparison, POCI is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

POCI’s TA Score shows that 6 TA indicator(s) are bullish while STXS’s TA Score has 5 bullish TA indicator(s).

  • POCI’s TA Score: 6 bullish, 4 bearish.
  • STXS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both POCI and STXS are a good buy in the short-term.

Price Growth

POCI (@Pharmaceuticals: Other) experienced а +1.01% price change this week, while STXS (@Pharmaceuticals: Other) price change was -19.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.51%. For the same industry, the average monthly price growth was +3.45%, and the average quarterly price growth was +18.53%.

Reported Earning Dates

POCI is expected to report earnings on Nov 16, 2026.

STXS is expected to report earnings on Feb 26, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (+1.51% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

POCI and

Correlation & Price change

A.I.dvisor tells us that POCI and NSYS have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POCI and NSYS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To POCI
1D Price
Change %
POCI100%
-0.99%
NSYS - POCI
26%
Poorly correlated
+1.96%
LUCD - POCI
22%
Poorly correlated
+9.15%
APYX - POCI
21%
Poorly correlated
-3.67%
STXS - POCI
21%
Poorly correlated
-5.56%
TMCI - POCI
20%
Poorly correlated
+5.53%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-5.56%
SMTI - STXS
38%
Loosely correlated
+2.94%
TWST - STXS
36%
Loosely correlated
-6.83%
CERS - STXS
35%
Loosely correlated
-8.49%
VCYT - STXS
33%
Poorly correlated
-1.91%
SHC - STXS
32%
Poorly correlated
-0.85%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPCF13.260.04
+0.30%
ProShares Ultra SpaceX ETF (SPCF)
PCLO24.97N/A
N/A
Virtus SEIX AAA Private Credit CLO ETF
XTWO48.28-0.09
-0.19%
BondBloxx Bloomberg Two Year Target Duration US Treasury ETF (XTWO)
JHML90.50-0.40
-0.44%
John Hancock Multifactor Large Cap ETF (JHML)
XKRE25.96-0.39
-1.49%
Corgi U.S. Regional Banks 2x Daily ETF (XKRE)